4//SEC Filing
CR Group L.P. 4
Accession 0001415889-24-010906
CIK 0001492674other
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 8:35 PM ET
Size
23.0 KB
Accession
0001415889-24-010906
Insider Transaction Report
Form 4
Transactions
- Award
Common Stock
2024-04-12+1,647,315→ 1,983,262 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.) - Award
Common Stock
2024-04-12+390,142→ 878,415 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Common Stock
2024-04-12+682,036→ 682,036 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-04-12+136,409→ 136,409 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.) - Award
Common Stock
2024-04-12+424,716→ 424,716 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Series A Convertible Preferred Stock
2024-04-12+17,160.48→ 28,035.73 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)From: 2024-04-12→ Common Stock (1,716,048 underlying)
CRG Partners III L.P.
10% Owner
Transactions
- Award
Common Stock
2024-04-12+424,716→ 424,716 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Common Stock
2024-04-12+136,409→ 136,409 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.) - Award
Common Stock
2024-04-12+390,142→ 878,415 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Series A Convertible Preferred Stock
2024-04-12+17,160.48→ 28,035.73 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)From: 2024-04-12→ Common Stock (1,716,048 underlying) - Award
Common Stock
2024-04-12+682,036→ 682,036 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-04-12+1,647,315→ 1,983,262 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
Capital Royalty L.P.
10% Owner
Transactions
- Award
Common Stock
2024-04-12+424,716→ 424,716 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Common Stock
2024-04-12+1,647,315→ 1,983,262 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.) - Award
Common Stock
2024-04-12+390,142→ 878,415 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Common Stock
2024-04-12+682,036→ 682,036 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-04-12+136,409→ 136,409 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.) - Award
Series A Convertible Preferred Stock
2024-04-12+17,160.48→ 28,035.73 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)From: 2024-04-12→ Common Stock (1,716,048 underlying)
Transactions
- Award
Common Stock
2024-04-12+682,036→ 682,036 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-04-12+1,647,315→ 1,983,262 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.) - Award
Common Stock
2024-04-12+390,142→ 878,415 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Common Stock
2024-04-12+424,716→ 424,716 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Common Stock
2024-04-12+136,409→ 136,409 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.) - Award
Series A Convertible Preferred Stock
2024-04-12+17,160.48→ 28,035.73 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)From: 2024-04-12→ Common Stock (1,716,048 underlying)
Transactions
- Award
Common Stock
2024-04-12+682,036→ 682,036 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-04-12+390,142→ 878,415 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Common Stock
2024-04-12+424,716→ 424,716 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Common Stock
2024-04-12+136,409→ 136,409 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.) - Award
Common Stock
2024-04-12+1,647,315→ 1,983,262 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.) - Award
Series A Convertible Preferred Stock
2024-04-12+17,160.48→ 28,035.73 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)From: 2024-04-12→ Common Stock (1,716,048 underlying)
Transactions
- Award
Common Stock
2024-04-12+136,409→ 136,409 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.) - Award
Common Stock
2024-04-12+390,142→ 878,415 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Common Stock
2024-04-12+682,036→ 682,036 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-04-12+424,716→ 424,716 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Series A Convertible Preferred Stock
2024-04-12+17,160.48→ 28,035.73 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)From: 2024-04-12→ Common Stock (1,716,048 underlying) - Award
Common Stock
2024-04-12+1,647,315→ 1,983,262 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)
Footnotes (4)
- [F1]Pursuant to that certain Securities Purchase Agreement, dated February 15, 2024, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III - Parallel Fund B (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares of common stock in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.
- [F2]CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
- [F3]Each share of Series A Convertible Preferred Stock (the "Series A Preferred") converts into 100 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series A Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 49.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 49.99% beneficial ownership limitation, as of April 12, 2024, the Series A Preferred held by the reporting persons can be converted into a maximum of 1,173,600 shares of common stock in the aggregate. The shares of Series A Preferred have no expiration date.
- [F4]The preferred stock has no expiration date.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001702352
Filing Metadata
- Form type
- 4
- Filed
- Apr 15, 8:00 PM ET
- Accepted
- Apr 16, 8:35 PM ET
- Size
- 23.0 KB